Actavis $ACT (renamed from Watson Pharma $WPI after merger) is one of numerous companies pursuing biosimilars, in collaboration with Amgen $AMGN. Here are there recent comments from the 1q-2013 earnings call (c/o SeekingAlpha). Note that their commercialization deal with Antares Pharma $ATRS for GELNIQUE was not discussed.
With the collaboration with Amgen, obviously, we've made a bet on 4 biosimilars in the oncology space. Those are progressing very nicely, with the first one going into Phase III during the quarter.
How confident are you that Amgen's interests are aligned with yours in terms of where you'd like to see the regulatory and legal landscape end up on biosimilars? I just want to make sure my own edification that they're not a biosimilar spy
I believe Amgen's interests are aligned with ours on biosimilars. They we have certain things that they believe strongly in that we talk to them about, and -- but I don't see them as a spy. I think they're actually a fantastic partner. We've had a great relationship. They're driving products with us to conclusion. They believe in the biosimilar opportunities that exist, not just in the U.S. but around the world, and so we don't find ourselves at odds with them
Probably the best statement to add to this is that the cornerstone of this agreement is the quality side of it. And they've driven the need to make sure the qualities are driven -- is driven into the biosimilar space just as they have into the originator brand space. So we see eye-to-eye on that. We work very aggressively together on trying to work on advancing the biosimilar space. But I think it's with a quality background, and I think that's going to help the American public as these biosimilars come to market in the future
How confident are you that Amgen's interests are aligned with yours in terms of where you'd like to see the regulatory and legal landscape end up on biosimilars? I just want to make sure my own edification that they're not a biosimilar spy
I believe Amgen's interests are aligned with ours on biosimilars. They we have certain things that they believe strongly in that we talk to them about, and -- but I don't see them as a spy. I think they're actually a fantastic partner. We've had a great relationship. They're driving products with us to conclusion. They believe in the biosimilar opportunities that exist, not just in the U.S. but around the world, and so we don't find ourselves at odds with them
Probably the best statement to add to this is that the cornerstone of this agreement is the quality side of it. And they've driven the need to make sure the qualities are driven -- is driven into the biosimilar space just as they have into the originator brand space. So we see eye-to-eye on that. We work very aggressively together on trying to work on advancing the biosimilar space. But I think it's with a quality background, and I think that's going to help the American public as these biosimilars come to market in the future
RSS Feed
